BioCentury
ARTICLE | Company News

BioView, Abbott deal

December 10, 2012 8:00 AM UTC

The companies partnered to develop an automated scanning solution to detect rearrangements in genes encoding anaplastic lymphoma kinase (ALK) in patients with advanced non-small cell lung cancer (NSCLC). BioView will be responsible for expanding approval of its Duet Automated Scanner to include automated imaging and analysis of Abbott's Vysis ALK Break Apart FISH Probe Kit. Abbott will then use the product in its clinical trials, while both companies will co-promote the product worldwide. The partners declined to disclose details. ...